作为一种新的老年治疗方法的SGLT2抑制剂
Zeynep Elif Yesilyurt-Dirican1,2, Ce Qi2, Yi-Chian Wang2
1Department of Pharmacology, Faculty of Pharmacy, Gazi University, Ankara, Türkiye.
npj aging
|May 10, 2025
概括
-葡萄糖共载体2 (SGLT2) 抑制剂,最初用于糖尿病,作为老年治疗药物显示出希望. 这些药物可能针对细胞衰老及其相关的分泌表型 (SASP),为衰老和疾病治疗提供新的途径.
科学领域:
- 老年学和分子生物学
- 药理学和治疗学 药理学和治疗学
背景情况:
- 细胞衰老,细胞分裂的不可逆转停止,通过衰老相关的分泌表型 (SASP) 促进衰老和慢性疾病.
- 老年疗法策略旨在通过向衰老细胞或他们的SASP来缓解衰老和疾病.
- -葡萄糖共载体2 (SGLT2) 抑制剂是一种具有已知的心血管和脏保护作用的抗糖尿病药物.
研究的目的:
- 审查-葡萄糖辅运输体2 (SGLT2) 抑制剂的新兴老年治疗潜力.
- 检查最新的研究,将SGLT2抑制剂与细胞衰老和SASP的抑制联系起来.
主要方法:
- 最近科学出版物和临床研究的文献综述.
- 对SGLT2抑制剂对细胞衰老标志物和SASP的影响数据的分析.
- 综合证据关于对衰老和与年龄有关的疾病的治疗影响.
主要成果:
- SGLT2 抑制剂显示出抑制细胞衰老的潜力.
- 这些药物可以抵消老化相关分泌表型 (SASP) 的促炎作用.
- 有证据表明,SGLT2抑制剂可以被重新定位为老年治疗药物.
结论:
- SGLT2 抑制剂代表了针对细胞衰老和衰老的有希望的治疗途径.
- 对SGLT2抑制剂的治疗机制和临床疗效的进一步研究是有必要的.
- 重用SGLT2抑制剂可能为管理与年龄相关的病理提供新的策略.
相关概念视频
Glucagon-like Receptor Agonists
270
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
270
Secondary Active Transport
6.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.6K
Oral Hypoglycemic Agents: Biguanides and Glitazones
141
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
141
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Glucose Transporters
22.2K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.2K
Dipeptidyl Peptidase 4 Inhibitors
136
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
136


